In Brief: Cytogen's ProstaScint
This article was originally published in The Gray Sheet
Executive Summary
Cytogen's ProstaScint: C.R. Bard will copromote the prostate cancer diagnostic capromab pendetide under a 10-year agreement announced Aug. 1. The deal calls for Bard to market the monoclonal antibody imaging agent to office and hospital-based urologists. Cytogen will be responsible for the completion of clinical trials, regulatory activities related to the PLA, manufacturing, distribution and marketing to the medical imaging community. Both companies will market the monoclonal antibody-based product to managed care organizations. Cytogen has said it plans initially to restrict availability of the imaging agent to certified sites. On July 22, FDA's Medical Imaging Drugs Advisory Committee unanimously recommended ProstaScint for detection of metastatic prostate cancer in high-risk patients to aid surgical staging and to detect recurrence of prostatic carcinoma...
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.